Bibliographic citations
Terrones, J., (2020). Efectividad del tadalafilo comparado con tamsulosina en pacientes con hipertrofia prostática benigna con síntomas moderados [Tesis, Universidad Privada Antenor Orrego - UPAO]. https://hdl.handle.net/20.500.12759/6720
Terrones, J., Efectividad del tadalafilo comparado con tamsulosina en pacientes con hipertrofia prostática benigna con síntomas moderados [Tesis]. : Universidad Privada Antenor Orrego - UPAO; 2020. https://hdl.handle.net/20.500.12759/6720
@mastersthesis{renati/379463,
title = "Efectividad del tadalafilo comparado con tamsulosina en pacientes con hipertrofia prostática benigna con síntomas moderados",
author = "Terrones Deza, Juan Manuel",
publisher = "Universidad Privada Antenor Orrego - UPAO",
year = "2020"
}
A prospective observational study was carried out in 60 patients with benign prostatic hypertrophy whit moderate symptoms alt the Hospital de Belen de Trujillo during the months of October to December 2019, 2 groups were studied, the first with 30 patients who took tamsulosin 0.4 mg daily for 4 weeks ( Age 67.50±6.96 years, prostate volume 67.30±84.23 cc, PSA 2.37±1.20 ng/ml, initial postvoid residue 57-80±33-69 ml), and the second group with 30 patients who took tadalafil 5 mg daily for 4 weeks ( Age 67.53±6.30 years, prostate volume 48.40±14.48 cc, PSA 2.04±1.21 ng/ml, initial postvoid residue 56.70±29.44 ml), there were no statistical differences in relation to the clinical characteristics of both groups (p>0.05). Both groups showed a decrease in the severity of symptoms evaluated by IPSS, in the Tamsulosin group it decreased from 11.87±2.81 to 6.90±3.06 and in the Tadalafil group it decreased from 11.97±2.68 to 7.57±2.73, no statistically significant difference was found after 4-week treatment between both groups (p>0.05). It is concluded that the effectiveness of tadalafil compared to that tamsulosin is similar in patients with benign prostatic hypertrophy with moderate symptoms at the Hospital Belen de Trujillo.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.